Hello, welcome to Shanghai new vigor Activated Carbon Co., Ltd. website, we will be happy to serve you!    中文    English
News center    HOME > News center > Corporate News

State Food and Drug Administration to implement the announcement

Notice of the State Administration of Food and Drug Administration on the Implementation of the relevant edition of the People's Republic of China Pharmacopoeia 2015 edition (No. 105 of 2015)

"People's Republic of China Pharmacopoeia" (hereinafter referred to as "Chinese Pharmacopoeia") 2015 edition has been issued by the State Food and Drug Administration No. 67 Announcement 2015, from December 1, 2015 onwards. The relevant matters concerning the implementation of the Chinese Pharmacopoeia 2015 edition are as follows:

First, the "Chinese Pharmacopoeia" is the drug development, production (import), management, use and supervision and management of relevant units should follow the statutory technical standards.

Second, the "Chinese Pharmacopoeia" 2015 edition, including the case, the text and general rules, since the date of implementation, all production of listed drug standards (including drug registration standards) should be the implementation of the Pharmacopoeia of the relevant general requirements.

 三、Where the "Chinese Pharmacopoeia" 2015 version of the collection of species, since the date of implementation, the original contained in the Pharmacopoeia Pharmacopoeia, Bureau (Department) awarded the same type of national drug standards at the same time abolished.

Where the "Chinese Pharmacopoeia" 2015 edition under the variety of products not contained specifications, the quality standards according to the version of "Chinese Pharmacopoeia" with the relevant requirements of the implementation of the specifications, according to the original approval documents.

Where the "Chinese Pharmacopoeia" 2015 edition is no longer contained in the calendar Pharmacopoeia has received varieties (due to security, effectiveness and other issues withdrawn from the city except), the new standard is not promulgated before the implementation of the original Pharmacopoeia standards, but should be consistent with the new version General requirements for pharmacopoeia.

四、Drug registration standards in the collection of test items more than (including different) Pharmacopoeia requirements or quality indicators strict pharmacopoeia requirements, the implementation of pharmacopoeia requirements should be based on the implementation of the original registration standards of the corresponding projects and indicators. Due to differences in materials and production processes lead to differences in testing items, production enterprises should be based on scientific, quality control of the principles of research, if necessary, to declare drugs to apply.

If the drug registration standard is less than the requirements of the Pharmacopoeia or the quality index is lower than the requirements of the Pharmacopoeia, the Pharmacopoeia shall be implemented.

五、"Chinese Pharmacopoeia" 2015 version of the date of release (including the date) before the approved drugs should be December 1, 2015 from the implementation of the new Pharmacopoeia corresponding requirements. In case of alteration of pharmaceutical prescription, raw and auxiliary materials and production technology, it shall, in accordance with the Measures for the Administration of Drug Registration, submit a supplementary application to the State Food and Drug Administration before December 1, 2015, and the examination and approval period The original standard, approval by the implementation of the new standards, approval should not immediately stop production.

Only concerned with the detection of the project, the index limit adjustment but does not involve the drug prescription, raw and auxiliary materials, production and process changes, should be implemented before the date of the provincial food and drug supervision and management departments (imported drugs reported to the State Food and Drug Administration) Filing.

六、The new drug registration application should be carried out in accordance with the relevant requirements of the new Pharmacopoeia. The technical review department shall conduct a review in accordance with the relevant requirements of the new Pharmacopoeia. Those who meet the requirements are not approved.

The technical review department has not yet completed the relevant technical review of the registration application, in accordance with the relevant requirements of the new Pharmacopoeia review; technical review departments have completed the relevant technical review of the Chinese Pharmacopoeia 2015 version of the date of publication (including the date) The registration application, drug approval within 6 months after listing should meet the relevant requirements of the new Pharmacopoeia.

七、According to the "Chinese Pharmacopoeia" 2015 edition of the revised content, pharmaceutical manufacturers should be in the above-mentioned period before the "Drug Registration Management" provides timely changes in the instructions and labeling of pharmaceutical applications. Drugs produced after the specified period of time must use the revised instructions and labels. For the generic name of the drug has been revised, its original name can be used as a transitional use of the name.

八、Pharmaceutical production (import) enterprises should actively do a good job in the implementation of the "Chinese Pharmacopoeia" 2015 edition of the preparatory work for the implementation of the new Pharmacopoeia in the implementation of the problems found in the local newspaper and provincial food and drug supervision and management departments, and should continue to improve the quality control and quality Standard research, and continuously improve the level of drug quality control.

九、The provincial food and drug supervision and management departments should cooperate with the "Chinese Pharmacopoeia" 2015 version of the publicity and implementation of the new version of the Pharmacopoeia to strengthen the supervision and guidance, timely collection and feedback related issues and opinions.

十、The National Pharmacopoeia Commission is responsible for organizing and coordinating the implementation and training of the Chinese Pharmacopoeia 2015 edition and the specific technical guidance in the implementation of the new Pharmacopoeia. In its website specifically to open up the "Chinese Pharmacopoeia Executive Column", in a timely manner to answer all the relevant issues reflected, and timely organization of the new version of the implementation of the special assessment and inspection.

Special announcement.

Attachment: 1. "Chinese Pharmacopoeia" 2015 version by the revised catalog

2."Chinese Pharmacopoeia" 2015 version is no longer contained varieties directory

Food and Drug Administration

July 15, 2015



  Legal Notices

     Welcome to www.xhlac.com ("this site"). This website is owned and managed by Shanghai New Activated Activated Carbon Co., Ltd. Any person who enters, views and uses this website is deemed to have read, understood, endorsed and accepted the entire contents of this Legal Notice and has complied with all applicable laws and regulations.

  Statement of rights

     (Hereinafter referred to as the "Company" or the "Company") reserves the right, title, copyrights, trademarks, and all rights to the entire contents of this website (including but not limited to text, images, layouts, programs and other content) Other rights. All intellectual property rights such as trademarks, designs and merchandise packaging appearing on this website are protected by law. No part of this organization or individual may reproduce, modify, reproduce, publish, distribute or otherwise use the contents of this website without any written permission.

     Where the infringement of the above rights of the Company, we will be held accountable for their legal responsibilities.

  Disclaimer

     The content on this website is for informational purposes only and is not a commitment or offer made by the Company.

     The Company has made reasonable efforts to review the contents of this website, but the Company makes no representations, warranties or warranties regarding the accuracy, timeliness, completeness, validity and non-infringement of the rights of others. Company may update or modify the contents of this website at any time without notice.

     This website may contain links or references to other websites, which are provided for the convenience of visitors to the Site, and the Company shall not be liable for any loss or damage to the contents of such sites and any damages or damages which may result. Other sites may not link to this website without our written permission.

     The Company shall not be liable for any decision or action taken by any organization or individual to rely on the contents of this website as a result of entering, browsing or using the Site. (Including but not limited to business interruption, loss of profits, loss of data and property) arising out of any direct, indirect, incidental and consequential damages to any third party arising out of the use of the contents of this website or the inability to access the Site Destruction, etc.), the company does not assume any responsibility.

  privacy protection

     We will collect some non-personal information during the visitor's visit to this site. This information does not relate to the personal information of the site visitors, but only helps us to understand the access to the site so that we can optimize the site accordingly.

     We do not collect personal information from visitors without the consent of our visitors. We will take reasonable precautions for e-mail, address and other personal information provided by visitors to this website for matters such as service or recruitment. Except as a result of the mandatory requirements of the law, the administrative or judicial authorities or the damage to the Company's interests by the visitors of this website, we will not publish or provide visitors to any third party without the consent of the visitors to this website Any personal information.

  Applicable law and dispute resolution

     Any dispute arising out of or in connection with the contents of this website or any of the contents of this website (including the above terms) shall be governed by the laws of the People's Republic of China and by the jurisdiction of the Shanghai New Activated Activated Carbon Company Limited.